Warning: The NCBI web site requires JavaScript to function. more...

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer

Mads Hald Andersen, Rikke B Soerensen, Jürgen C Becker, Per thor Straten

J Transl Med. 2006; 4: 38. Published online 2006 September 4. doi: 10.1186/1479-5876-4-38

PMCID:: PMC1564416

Is Cited by the Following 3 Articles in this Archive:

Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients

Jun-ichi Kobayashi, Toshihiko Torigoe, Yoshihiko Hirohashi, Satomi Idenoue, Akihiro Miyazaki, Akira Yamaguchi, Hiroyoshi Hiratsuka, Noriyuki Sato

J Transl Med. 2009; 7: 1. Published online 2009 January 6. doi: 10.1186/1479-5876-7-1

PMCID:: PMC2627828

Abstract Full Text PDF–616K

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

Tetsuhiro Tsuruma, Yuji Iwayama, Tosei Ohmura, Tadashi Katsuramaki, Fumitake Hata, Tomohisa Furuhata, Koji Yamaguchi, Yasutoshi Kimura, Toshihiko Torigoe, Nobuhiko Toyota, Atsuhito Yagihashi, Yoshihiko Hirohashi, Hiroko Asanuma, Kumiko Shimozawa, Minoru Okazaki, Yasuhiro Mizushima, Naohiro Nomura, Noriyuki Sato, Koichi Hirata

J Transl Med. 2008; 6: 24. Published online 2008 May 10. doi: 10.1186/1479-5876-6-24